Join
Live feed
·
PRReleasevia Quantisnow
Neurocrine Biosciences Inc. logo

Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups

ByQuantisnow·Wall Street's wire, on your screen.
NBIX· Neurocrine Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NBIX (Neurocrine Biosciences Inc.) and more on Quantisnow.